ReviewDrug news & perspectives2009
The role of X-box binding protein-1 in tumorigenicity.
Review in Drug news & perspectives, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 68 citations in OpenAlex.
- CPUK02 sensitizes U87 glioblastoma cell lines to TMZ treatment via autophagy flux inhibition.Molecular biology research communications · 2026Article
- Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson's disease treatment.Journal of translational medicine · 2024Article
- The unfolded protein response (UPR) pathway: the unsung hero in breast cancer management.Apoptosis : an international journal on programmed cell death · 2023Review
- Mechanism and Role of Endoplasmic Reticulum Stress in Osteosarcoma.Biomolecules · 2022Review
- TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma.Frontiers in genetics · 2022Article
- Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression.Cancers · 2019Review
- Article
- Unravel the molecular mechanism of XBP1 in regulating the biology of cancer cells.Journal of Cancer · 2019Review
- Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells.Journal of cell science · 2018Article
- Targeting protein quality control pathways in breast cancer.BMC biology · 2017Review
- EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer.Oncotarget · 2017Article
- Identification of XBP1-u as a novel regulator of the MDM2/p53 axis using an shRNA library.Science advances · 2017Article
- Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer.Journal for immunotherapy of cancer · 2017Review
- Nuclear expression of XBP1s is correlated with breast cancer survival: a retrospective analysis based on tissue microarray.OncoTargets and therapy · 2017Article
- Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma.Molecular cancer therapeutics · 2016Article
- Molecular Pathways: Immunosuppressive Roles of IRE1α-XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Review
- Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy.Oncoimmunology · 2016Article
- Endocrine resistance in breast cancer--An overview and update.Molecular and cellular endocrinology · 2015Review
- Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.International journal of molecular sciences · 2015Article
- Interplay between unfolded protein response and autophagy promotes tumor drug resistance.Oncology letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Rapid growth of a tumor can overwhelm the vasculature that supplies it with nutrients and oxygen. Inside such tumors, cells undergo endoplasmic reticulum stress but can survive such adverse microenvironments by an adaptive mechanism called the unfolded protein response (UPR). X-box binding protein-1 (XBP-1) is a critical transcriptional activator of the UPR and is responsible for regulating the function of genes in cell survival. An unconventional splicing of the XBP-1(U) messenger RNA (mRNA) results in two proteins: XBP-1(S) that is often increased in a variety of human cancers and any translated proteins from the unspliced XBP-1(U) mRNA that acts as a dominant negative of endogenous XBP-1(S) action. In cancer cells, overexpression of XBP-1 can confer drug resistance by preventing drug-induced cell-cycle arrest and mitochondrial permeability and apoptosis, while downregulation of XBP-1 increases the sensitivity to killing by hypoxia. XBP-1 is also implicated in cellular de-differentiation, oncovirus infection and the epithelial-to-mesenchymal transition. Given that XBP-1 mediates a wide range of responses in tumorigenesis, it is logical to focus on XBP-1 as an anticancer therapeutic target. Furthermore, combining inhibitors of XBP-1 with other anti-UPR drugs may enhance the activity of some antineoplastic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.